Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 67, Number 7, October 10, 2006
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nash, T. E.
Right arrow Articles by Garcia, H. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nash, T. E.
Right arrow Articles by Garcia, H. H.
Related Collections
Right arrow Parasitic infections
Right arrow All Epilepsy/Seizures
NEUROLOGY 2006;67:1120-1127
© 2006 American Academy of Neurology
Views & Reviews

Treatment of neurocysticercosis

Current status and future research needs

T. E. Nash, MD, G. Singh, MD, A. C. White, MD, V. Rajshekhar, MCh, J. A. Loeb, MD, PhD, J. V. Proaño, MD, O. M. Takayanagui, MD, A. E. Gonzalez, DVM, PhD, J. A. Butman, MD, PhD, C. DeGiorgio, MD, O. H. Del Brutto, MD, A. Delgado-Escueta, MD, PhD, C.A.W. Evans, MD, PhD, R. H. Gilman, MD, DTMH, S. M. Martinez, MD, M. T. Medina, MD, E. J. Pretell, MD, J. Teale, PhD and H. H. Garcia, MD, PhD

From the Laboratory of Parasitic Diseases (T.E.N.), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; Dayanand Medical College and Hospital (G.S.), Ludhiana, Punjab, India; Infectious Disease Section (A.C.W.), Department of Medicine, Baylor College of Medicine, Houston, TX; Department of Neurological Sciences (V.R.), Christian Medical College and Hospital, Vellore, India; Department of Neurology and Center for Molecular Medicine and Genetics (J.A.L.), Wayne State University School of Medicine, Detroit, MI; Medical Research Unit for Neurologic Diseases (J.V.P.), Hospital de Especialidades, Centro Medico Nacional Siglo XXI, Mexican Institute of Social Security, Mexico City; Department of Neurology (O.M.T.), School of Medicine of Ribeirao Preto, Universidade de Sao Paulo, Ribeirão Preto, Brazil; School of Veterinary Medicine (A.E.G.), Universidad Nacional Mayor de San Marcos, Lima, Perú; Department of International Health (A.E.G., R.H.G., H.H.G.), Johns Hopkins University Bloomberg School of Hygiene and Public Health, Baltimore, MD; Diagnostic Radiology Department (J.A.B.), Warren G. Magnuson Clinical Center, NIH, Bethesda, MD; Department of Neurology (C.D.G., A.D.-E.), Reed Neurological Research Center, UCLA, Los Angeles, CA; Department of Neurological Sciences (O.H.D.B.), Hospital-Clínica Kennedy, Guayaquil, Ecuador; VA Epilepsy Center of Excellence (A.D.-E.), Los Angeles, CA; University of Cambridge Clinical School (C.A.W.E.), Cambridge, and Department of Infectious Diseases and Microbiology, Imperial College London, London, UK; Department of Microbiology (R.H.G., E.J.P., H.H.G.), Universidad Peruana Cayetano Heredia, Lima, Perú; Cysticercosis Unit (S.M.M., H.H.G.), Instituto Especializado en Ciencias Neurológicas, Lima, Peru; Universidad Nacional Autonoma de Honduras (M.T.M.), Tegucigalpa, Honduras; and Department of Microbiology and Immunology (J.T.), University of Texas Health Science Center, San Antonio.

Address correspondence and reprint requests to Dr Nash, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; e-mail: tnash{at}niaid.nih.gov

Here we put forward a roadmap that summarizes important questions that need to be answered to determine more effective and safer treatments. A key concept in management of neurocysticercosis is the understanding that infection and disease due to neurocysticercosis are variable and thus different clinical approaches and treatments are required. Despite recent advances, treatments remain either suboptimal or based on poorly controlled or anecdotal experience. A better understanding of basic pathophysiologic mechanisms including parasite survival and evolution, nature of the inflammatory response, and the genesis of seizures, epilepsy, and mechanisms of anthelmintic action should lead to improved therapies.

Supported by the Office of Rare Diseases (NIH), National Institute of Allergy and Infectious Diseases/Laboratory of Parasitic Diseases (NIH), Universidad Peruana Cayetano Heredia (Lima, Peru), and Instituto de Ciencias Neurologicas (Lima, Peru).

Disclosure: The authors report no conflicts of interest.

Received January 6, 2006. Accepted in final form June 7, 2006.




This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Carpio, E A Kelvin, E Bagiella, D Leslie, P Leon, H Andrews, W A Hauser, and the Ecuadorian Neurocysticercosis Group
Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial
J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1050 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Thussu, A Chattopadhyay, I M S Sawhney, and N Khandelwal
Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy
J. Neurol. Neurosurg. Psychiatry, March 1, 2008; 79(3): 272 - 275.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.